UCB (OTCMKTS:UCBJF) Shares Gap Down - What's Next?

UCB SA (OTCMKTS:UCBJF - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $201.96, but opened at $195.21. UCB shares last traded at $199.89, with a volume of 89 shares trading hands.

Analyst Ratings Changes

Separately, Morgan Stanley raised shares of UCB to an "overweight" rating in a research report on Monday, June 23rd.

UCB Price Performance

The stock's 50-day simple moving average is $176.83 and its 200 day simple moving average is $182.54. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.